download sport betting app
2025-01-11   

download sport betting app Leo Daily Horoscope Today, December 27, 2024 predicts health at your sideLuigi Mangione’s face is now familiar worldwide, following his arrest for allegedly killing UnitedHealthcare CEO Brian Thompson last week in Manhattan. But new details on the life and background of the Ivy League-educated 26-year-old are still emerging by the hour. Mangione, in custody in Pennsylvania following a five-day manhunt and facing a second-degree murder charge in New York, struggled with police and yelled out as he entered an extradition hearing on Tuesday. Those who knew Mangione are now trying to reconcile the friendly computer science major with the suspect who allegedly shot and killed Thompson and was arrested carrying a short manifesto criticizing health insurance companies for putting profits above care and specifically singling out UnitedHealthcare, according to the New York Times and CNN. Well-known family Mangione was born in 1998 to Louis and Kathleen Mangione, and was part of a well-known family in Maryland that owned a wide range of businesses. Luigi’s grandfather, Nick Mangione Sr., and his wife purchased a golf course and country club in Howard County in the 1970s. It included a 220-room hotel, a 10,000-square-foot ballroom and an 85-seat amphitheater, according to the Washington Post. They had five daughters and five sons, including Luigi’s father Louis. They later bought another country club and a radio station in the 1980s. Mangione Sr. died in 2008, but his children have continued to run the family businesses. Thomas J. Maronick Jr., a lawyer and radio host who knew Mangione Sr., praised the family, describing them as “incredibly generous.” He said they were generous with charities. Maronick Jr. said he was shocked that Luigi Mangione has been named as the shooter. “Given the family, and how generous and supportive of charity they are, and the esteem their name carries in Maryland, it’s the last person you’d expect,” he said. Promising childhood before disappearance Former classmates at the Gilman School, an all-boys, $37,000 a year private school in Baltimore, told the New York Times that Luigi Mangione was intelligent. They said he made mobile apps before college, and participated in clubs including model U.N. and robotics. Mangione was also an athlete, and was on the wrestling team. Former classmate Aaron Cranston told the Times he became friends with Mangione in high school, describing him as perhaps the “smartest” at the elite private school. “He was a big believer in the power of technology to change the world,” Cranston told the paper. In his senior yearbook page, Mangione thanked his parents for sending him to Gilman, saying the school was “the best thing that’s ever happened to me.” “Thanks for dealing with me these past 18 years,” Mangione wrote to his parents. “I cannot thank you enough for supporting me along the way.” The yearbook page shows he fulfilled his community service requirement at the Maryland nursing home company Lorien Health Services, which his father was an owner of, according to the Times. After graduating and giving the valedictorian speech at Gilman in 2016, Mangione attended the University of Pennsylvania where he majored in computer science. He later got his master’s in computer and information science. Mangione was interested in video game development, and his LinkedIn profile states that he fixed 300 bugs as an intern for the company Firaxis Games in the video game “Civilization VI.” His LinkedIn page shows Mangione worked as a software engineer for the California-based company TrueCar for several years starting in 2020. In recent years, those who knew him said Mangione was dealing with significant back pain. He lived for six months in Honolulu, moving into a “co-living” space called Surfbreak that caters to remote workers. Surfbreak’s founder, R.J. Martin, told the Times that Mangione was a smart, accomplished and upbeat engineer. Fellow Surfbreak resident Jackie Wexler told the Honolulu Civil Beat that Mangione was “just such a thoughtful and deeply compassionate person at everything he did.” He didn’t complain about his back pain, but it had a major impact on his life, Martin said. “He knew that dating and being physically intimate with his back condition wasn’t possible,” Martin told the Times. “I remember him telling me that, and my heart just breaks.” The now-charged suspect’s GoodReads account paints a complex picture. It includes praise for a the book “Industrial Society and Its Future” by Ted Kaczynski, also known as the Unabomber. His reading history included several books on dealing with chronic back pain, and his X profile shows an X-ray image of a spinal fusion surgery, though it’s unconfirmed if the image actually depicts Mangione. Friiends told the Times that Mangione’s family was unaware of his whereabouts before his arrest on Monday. His mother, Kathleen, reported to San Francisco police that her son was missing on Nov. 18, the San Francisco Standard reported . Public records suggest Mangione may have relatives in San Francisco, the Standard added.

NEW YORK , Dec. 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Southwest Airlines Co. (NYSE: LUV) in connection with Southwest Airlines' information technology infrastructure impacting the Company's business, operations, and stock price. If you currently own shares of Southwest Airlines stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=10716 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com . Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York , NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-law-firm-announces-investigation-of-breaches-of-fiduciary-duties-by-the-directors-and-officers-of-southwest-airlines-co--luv-302337738.html SOURCE THE ROSEN LAW FIRM, P. A.The United States Space Force is a critical component of our nation’s defense. As the newest branch of the U.S. military, the Space Force is responsible for protecting and defending our nation’s interests in space. This includes everything from satellite communications and navigation to missile warning and defense. The Space Force is also working to develop new capabilities, such as agile protect-and-defend systems, which enable us to stay ahead of emerging threats, hold adversary space systems at risk and be prepared if deterrence fails. As the director of the U.S. Space Force’s Space Rapid Capabilities Office (Space RCO), I have had the privilege of witnessing firsthand the incredible potential of collaboration between the government and the space industry. Established in 2018, Space RCO is a direct reporting unit of the Space Force, responsible for acquiring space and ground systems that protect and defend against threats. Our mission is to rapidly develop and field space capabilities that meet the evolving needs of our nation’s defense. In the state of New Mexico, where Space RCO is headquartered, we have collaborated with the Air Force Research Laboratory, with the Space Systems Command Innovations and Prototyping Delta and with local educational institutions, such as the University of New Mexico and Central New Mexico Community College, to stay on the leading edge of innovation. Over the past five years, Space RCO has tripled in size, attracting top talent from across the nation. Our military personnel have achieved an impressive 100% promotion rate, and our civilians have been recognized for their outstanding contributions at the Space Force level. This success is a testament to the dedication and expertise of our team, as well as the support of our local partnerships. In today’s world, space is no longer a sanctuary but a contested domain. The Space Force is working to ensure that we maintain our advantage in space, with Space RCO playing a critical role. I am proud to be a part of this team, and I am committed to continuing our work to protect and defend our nation’s interests in space. One of the key factors that sets Space RCO apart is our commitment to collaboration with the space industry. We believe that by working together with industry partners, we can tap into the latest innovations and expertise and accelerate the development of advanced space capabilities. This approach has proven to be highly successful, with our partnerships yielding significant benefits in terms of speed, agility and cost-effectiveness. Collaboration with the space industry is vital for several reasons. First, it allows us to leverage the expertise and resources of industry partners who bring a wealth of knowledge and experience to the table. This enables us to develop and field space capabilities that are tailored to meet the specific needs of our nation’s defense. Second, collaboration fosters a spirit of innovation and experimentation, which is essential for staying ahead of the curve in the rapidly-evolving space domain. Space RCO is a vital component of the Space Force, and our commitment to collaboration with the space industry is a key factor in our success. By working together, we can unlock the full potential of space-based capabilities and ensure that our nation remains safe and secure in the face of emerging threats. As we continue to face new challenges in the space domain, I am confident that with the help of our industry partners, we will continue to lead the Space Force in shaping the future of space-based defense. Kelly D. Hammett, a member of the Senior Executive Service, is Director of the Space Rapid Capabilities Office at Kirtland Air Force Base in New Mexico. Hammett leads the Air Force’s center of expertise for directed energy technology, developing and transitioning research technologies into military systems. He is responsible for more than 960 military and civilian scientists, engineers, contractors, and support people and an annual budget exceeding $267 million. He manages numerous state-of-the-art research laboratories and testing structures at Kirtland AFB, and several unique facilities, which include the Starfire Optical Range at Kirtland AFB; a testing site at the U.S. Army’s White Sands Missile Range in New Mexico; and the Air Force Maui Optical and Supercomputing Site in Hawaii.

If you've been waiting for a Black Friday deal on a robot vacuum that can handle both dry and wet cleaning, this Shark combo deal is worth your attention. Right now the Shark Robot Vacuum & Mop combo is just $349 at Amazon , which is 50% off. You're getting a capable 2-in-1 cleaner for half its usual price — and just in time for holiday hosting season. Having one device that can both vacuum and mop is a massive convenience for any household. This Shark model brings that versatility without the usual premium price tag, especially with this Black Friday discount. The standout feature here is the true 2-in-1 functionality. Unlike some combo units that just drag a wet cloth around, this Shark actually vacuums and mops properly, with separate tanks for clean and dirty water. The smart mapping technology means it learns your home's layout, making cleaning more efficient with each run. What's particularly clever is how it handles different floor types. The robot automatically knows when it's on carpet versus hard floors, adjusting its cleaning method accordingly. For homes with mixed flooring, this intelligence saves you from having to constantly adjust settings or block off areas. Voice control through Alexa or Google Assistant lets you start cleaning with a simple command, while the app gives you precise control over cleaning schedules and zones. You can set up no-go areas for carpets when mopping, or create specific cleaning routines for different rooms. At $349, the Shark Robot Vacuum & Mop robot offers serious value for anyone wanting to automate their floor cleaning.Texas' abortion pill lawsuit against New York doctor marks new challenge to interstate telemedicine Texas has sued a New York doctor for prescribing abortion pills to a Texas woman via telemedicine. It appears to be the first challenge in the U.S. to a state shield law that's intended to protect prescribers in Democratic-controlled states from being punished by states with abortion bans. Prescriptions like these, made online and over the phone, are a key reason that the number of abortions has increased across the U.S. even after state bans started taking effect. Most abortions in the U.S. involve pills rather than procedures. Anti-abortion groups are increasingly focusing on the rise of pills. Syrians cheer end of 50 years of Assad rule at first Friday prayers since government fell DAMASCUS (AP) — Exuberant Syrians observed the first Friday prayers since the ouster of President Bashar Assad, gathering in the capital’s historic main mosque, its largest square and around the country to celebrate the end of half a century of authoritarian rule. The newly installed interim prime minister delivered the sermon at the Umayyad Mosque, declaring that a new era of “freedom, dignity and justice” was dawning for Syria. The gatherings illustrated the dramatic changes that have swept over Syria less than a week after insurgents marched into Damascus and toppled Assad. Amid the jubilation, U.S. Secretary of State Antony Blinken met with allies around the region and called for an “inclusive and non-sectarian” interim government. US military flies American released from Syrian prison to Jordan, officials say WASHINGTON (AP) — The U.S. military has brought an American who was imprisoned in Syria for seven months out of the country. That's according to two U.S. officials, who said Friday that Travis Timmerman has been flown to Jordan on a U.S. military helicopter. The 29-year-old Timmerman told The Associated Press earlier Friday he had gone to Syria on a Christian pilgrimage and was not ill-treated while in a notorious detention facility operated by Syrian intelligence. He said he was freed by “the liberators who came into the prison and knocked the door down (of his cell) with a hammer.” New Jersey governor wants more federal resources for probe into drone sightings TOMS RIVER, N.J. (AP) — New Jersey Gov. Phil Murphy has asked the Biden administration to put more resources into the ongoing investigation of mysterious drone sightings being reported in the state and other parts of the region. Murphy, a Democrat, made the request in a letter Thursday, noting that state and local law enforcement remain “hamstrung” by existing laws and policies in their efforts to successfully counteract any nefarious drone activity. Murphy and other officials say there is no evidence that the drones pose a national security or a public safety threat. A state lawmaker says up to 180 aircraft have been reported to authorities since Nov. 18. Nancy Pelosi hospitalized after she 'sustained an injury' from fall on official trip to Luxembourg WASHINGTON (AP) — Former House Speaker Nancy Pelosi has been hospitalized after she “sustained an injury” during an official engagement in Luxembourg, according to a spokesman. Pelosi is 84. She was in Europe to mark the 80th anniversary of the Battle of the Bulge in World War II. Her spokesman, Ian Krager, did not describe the nature of her injury or give any additional details, but a person familiar with the incident said that Pelosi tripped and fell while at an event with the other members of Congress. The person requested anonymity to discuss the fall because they were not authorized to speak about it publicly. Russia targets Ukrainian infrastructure with a massive attack by cruise missiles and drones KYIV, Ukraine (AP) — Russia has launched a massive aerial attack against Ukraine. Ukrainian President Volodymyr Zelenskyy says Russia fired 93 cruise and ballistic missiles and almost 200 drones in Friday's bombardments. He says it is one of the heaviest bombardments of the country’s energy sector since Russia’s full-scale invasion almost three years ago. He says Ukrainian defenses shot down 81 missiles, including 11 cruise missiles that were intercepted by F-16 warplanes provided by Western allies earlier this year. Zelenskyy renewed his plea for international unity against Russian President Vladimir Putin. But uncertainty surrounds how the war might unfold next year. President-elect Donald Trump has vowed to end the war and has thrown into doubt whether vital U.S. military support for Kyiv will continue. Trump’s lawyers rebuff DA's idea for upholding his hush money conviction, calling it 'absurd' NEW YORK (AP) — President-elect Donald Trump’s lawyers are again urging a judge to throw out his hush money conviction. In a court filing Friday, they balked at the prosecution’s “absurd” idea for preserving the verdict by treating the case the way some courts do when a defendant dies before sentencing. The Manhattan district attorney’s office is asking Judge Juan M. Merchan to “pretend as if one of the assassination attempts against President Trump had been successful,” Trump’s lawyers wrote in a blistering 23-page response. In court papers made public Tuesday, District Attorney Alvin Bragg’s office proposed an array of options for keeping the historic conviction on the books after Trump’s lawyers filed paperwork earlier this month asking for the case to be dismissed. Some in seafood industry see Trump as fishermen's friend, but tariffs could make for pricier fish PORTLAND, Maine (AP) — The incoming administration of President-elect Donald Trump is likely to bring big changes to seafood, one of the oldest sectors of the U.S. economy. Some in the industry believe the returning president will be more responsive to its needs. Economic analysts paint a more complicated picture, as they fear Trump’s pending trade hostilities with major trading partners Canada and China could make an already pricy kind of protein more expensive. Conservationists also fear Trump’s emphasis on deregulation could jeopardize fish stocks already in peril. But many in the commercial fishing and seafood processing industries said they expect Trump to allow fishing in protected areas and crack down on offshore wind expansion. OpenAI's legal battle with Elon Musk reveals internal turmoil over avoiding AI 'dictatorship' A 7-year-old rivalry between tech leaders Elon Musk and Sam Altman over who should run OpenAI and best avoid an artificial intelligence ‘dictatorship’ is now heading to a federal judge. The development comes as Musk seeks to halt the ChatGPT maker’s ongoing conversion into a for-profit company. Musk was an early OpenAI investor and board member. But he sued the artificial intelligence company earlier this year. He has since escalated the dispute, adding new claims and asking for a court order that would stop OpenAI’s plans to convert itself into a for-profit business more fully. OpenAI filed its response in court Friday. Paula Abdul settles lawsuit alleging sexual assault by 'American Idol' producer Nigel Lythgoe LOS ANGELES (AP) — Paula Abdul and former “American Idol” producer Nigel Lythgoe have agreed to settle a lawsuit in which she alleged he sexually assaulted her in the early 2000s when she was a judge on the show. Abdul filed a notice of settlement in a Los Angeles court Thursday. The lawsuit filed nearly a year ago had also accused Lythgoe of sexually assaulting Abdul after she left “American Idol” and became a judge on Lythgoe’s other show “So You Think You Can Dance.” Lythgoe said at the time that the allegations were “an appalling smear.” Both sides said in statements Friday that they were glad to put the case behind them.Irrigation Automation Global Market to Surge from $5.12 Billion in 2023 to $6.07 Billion Reflecting CAGR of 18.5%JEDDAH, Saudia Arabia, Dec. 10, 2024 (GLOBE NEWSWIRE) -- “Saudia,” the national flag carrier of Saudi Arabia, is proud to announce another year of significant fleet expansion and modernization. Over the past two years, the airline introduced several strategic partnerships to further Saudia Group’s objective of connecting the world with the Kingdom and supporting key pillars of Saudi Vision 2030 , while simultaneously enhancing comfort and efficiency for Saudia guests. Notable expansion and modernization initiatives include: Airbus Agreement: Saudia has signed a historic deal for 105 aircraft , the largest in Saudi aviation history. These aircraft will be distributed between Saudia and flyadeal, the group's low-cost carrier. Saudia will acquire 54 A321neo aircraft, while flyadeal will receive 12 A320neo and 39 A321neo aircraft. These aircraft feature spacious cabins and interior designs and equipped with the latest amenities and technology, while emitting 20 percent less fuel burn and carbon emissions than previous generations. Largest Investment in Guest Experience : Saudia has announced its largest investment to date in enhancing guest experience, highlighted by the introduction of a groundbreaking AI-powered "Travel Companion." This innovative technology leverages Saudi Arabia's rich cultural heritage and reliable data to provide an immersive, personalized travel experience. By utilizing data-driven personalization and universal integration, the virtual travel companion simplifies travel planning for visitors. The investment also includes the transformation of business class cabins, the introduction of high-speed in-flight internet, and unparalleled onboard entertainment options. This landmark investment underscores Saudia’s commitment to delivering a seamless and exceptional travel experience for its guests. Seat Retrofit Program: Saudia joined forces with Collins Aerospace to introduce state-of-the-art Business and Economy Class seats and retrofit seat enhancements. This program aims to improve functionality and aesthetics for Saudia’s current Airbus A330 and Boeing 777 fleet. Additionally, Saudia Technic will establish localized repair capabilities and select spare manufacturing capabilities, optimizing in-house repair capabilities and streamlining product support. B oeing Dreamliner Agreement: Saudia and Boeing announced the order of 49 fuel-efficient 787 Dreamliner aircraft by 2026, helping Saudia grow its long-haul fleet, improving efficiency, range, and flexibility. In-Flight Entertainment: Saudia announced a partnership with Astrova, Panasonic Avionics’ next-generation IFE seat-end solution. This collaboration will bring industry-leading 4K OLED screens, Panasonic Avionics’ latest Bluetooth technology, programmable LED lighting, and 100W direct current USB-C power to Saudia’s fleet, creating a fully immersive onboard entertainment experience. These strategic partnerships and investments underscore Saudia’s commitment to providing an exceptional travel experience for guests while optimizing operational efficiency and modernization across its growing fleet. For more details on Saudia’s aircraft and available experiences, or to book travel, visit https://www.saudia.com/pages/experience . About Saudia Saudia (Saudia Airlines) is the national flag carrier of the Kingdom of Saudi Arabia. Established in 1945, the company has grown to become one of the Middle East’s largest airlines. Saudia has invested significantly in upgrading its aircraft and currently operates one of the youngest fleets. The airline serves an extensive global route network covering around 100 destinations across four continents, including all 28 domestic airports in Saudi Arabia. A member of the International Air Transport Association (IATA) and the Arab Air Carriers Organization (AACO), Saudia has also been a member airline in SkyTeam, the second largest alliance, since 2012. Saudia was recently recognized as the World’s Most Improved Airline 2024 by Skytrax, marking the third time it has received this accolade, alongside 14 other distinguished awards. Saudia has been honored as the World Class Airline for 2024 at The APEX Official Airline RatingsTM awards, marking the third consecutive year the airline has received this prestigious recognition. Additionally, ranked top among global airlines for best on-time performance (OTP) according to a report by Cirium. For more information on Saudia, please visit www.saudia.com . Media Center Saudi Arabian Airlines Headquarters Jeddah 21231, Kingdom of Saudi Arabia Email: mediacenter@saudia.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9d017fc0-4a0b-4372-8843-fbbc7a8089ff

Man City collapse ‘difficult to swallow’ – Pep Guardiola

De'Vondre Campbell's mid-game quitting overshadowed the 49ers' offensive woesUnderstanding Nifty: A Simple Guide for Everyone

CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH CRENESSITY is expected to be commercially available in approximately one week Rare Pediatric Disease Priority Review Voucher granted in connection with approval SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: The CAHtalyst Pediatric study met its primary endpoint, with CRENESSITY significantly decreasing androstenedione levels from baseline to Week 4 versus patients taking placebo who experienced a substantial increase in androstenedione levels. Children taking CRENESSITY were also able to significantly reduce their GC doses at Week 28 while maintaining or improving androgen levels, a key secondary endpoint. Children taking CRENESSITY saw approximately four times greater reduction in androstenedione compared with those taking placebo. Approximately four times greater steroid dose reduction in children taking CRENESSITY was seen compared with those taking placebo. Children taking CRENESSITY saw approximately 12 times greater reduction in 17-hydroxyprogesterone (17-OHP) compared with those taking placebo. Headache, abdominal pain, fatigue, nasal congestion and nosebleed were the most common adverse drug reactions (ADRs) among the pediatric population treated with CRENESSITY. Most side effects were temporary and mild to moderate in severity. Phase 3 CAHtalyst Adult Study: The CAHtalyst Adult study met its primary endpoint with CRENESSITY enabling significant GC dose reductions at Week 24 (while maintaining or improving baseline androstenedione levels) and key secondary endpoint of decreasing androstenedione levels at Week 4. A significantly higher number of patients taking CRENESSITY (63%) achieved a GC dose in the physiologic range while androstenedione was maintained or improved compared with patients taking placebo (18%). Approximately two times greater steroid dose reduction was seen in people taking CRENESSITY compared with those taking placebo. People taking CRENESSITY saw an eight times greater reduction in androstenedione compared with those taking placebo. People taking CRENESSITY saw a 37 times greater reduction in 17-OHP compared with those taking placebo. Fatigue, headache, dizziness, joint pain, back pain, decreased appetite and muscle pain were the most common ADRs in the CRENESSITY treatment group. Most side effects were temporary and mild to moderate in severity. CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.TEHRAN – Iran’s Foreign Ministry has issued a strong condemnation of the recent attacks by the Israeli regime on Yemen, denouncing these assaults as a severe breach of international norms and principles. In a statement on Thursday, spokesperson Esmail Baqaei elaborated that these attacks, orchestrated with the support and complicity of the United States and Britain, violate international laws and the United Nations Charter. He criticized the UN’s inaction, asserting that the organization’s lack of response to the increasing violations and crimes of the Israeli regime “contradicts the responsibilities and duties of the organization as per the UN Charter.” Highlighting the ongoing genocide in Gaza, Baqaei emphasized that the repeated attacks on Yemen’s civilian infrastructure are part of a malicious Israeli policy aimed at weakening Islamic nations. “The Organization of Islamic Cooperation (OIC) and other regional and international bodies must act immediately to address these aggressions,” the diplomat added. The spokesperson also underscored that these violations constitute a clear breach of international peace and security, categorizing them as “undeniable crimes against Yemen’s resilient people, who have steadfastly supported the oppressed Palestinians against occupation and genocide.” The condemnation arose in reaction to airstrikes carried out by the Israeli regime on Thursday, which hit several locations in Yemen, notably Sana’a International Airport and three critical ports. Reports indicate that the airport was struck by more than six attacks, with further strikes affecting the nearby al-Dailami air base. Additional airstrikes were reported on a power station in Hudaydah, as well as military infrastructure at the Salif and Ras Kanatib ports. Casualty reports note that two individuals were killed in the airport strikes, one in the port attacks, and 11 others were injured.Key LTE Advanced Pro Market Trend 2024-2033: Advancements in Wi-Fi Router Technology

From the Middle Out and Bottom Up

John Kirby grilled on mysterious New Jersey drone sightings: 'Why don't we know?'

Providence, Oklahoma hope key players are back in Bahamas

Related hot word search:

Previous: does sport betting get taxed
Next: draftkings sport betting